Novo Nordisk A/S (NY: NVO )
68.14 USD +0.63 (+0.93%) Official Closing Price Updated: 7:00 PM EST, Dec 2, 2020 Add to My Watchlist
Press releases about Novo Nordisk A/S
EMISPHERE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emisphere Technologies, Inc. - EMIS
November 17, 2020
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emisphere Technologies, Inc. (OTC: EMIS) to...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Emisphere Technologies, Inc. Buyout
November 12, 2020
Emisphere Technologies, Inc. (OTC:EMIS) INVESTOR NOTICE: Abraham, Fruchter & Twersky, LLP Is Investigating the Sale of Emisphere and Encourages Investors to Contact the Firm
November 09, 2020
EMISPHERE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EMIS and Encourages Investors to Contact the Firm
November 09, 2020
(EMIS) Alert: Johnson Fistel Investigates Proposed Sale of Emisphere; Are Shareholders Getting a Fair Deal?
November 06, 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Emisphere Technologies (Other OTC: EMIS) ("Emisphere" or the "Company") breached their...
Thinking about trading stocks or options in Overstock.com, Novo Nordisk, Chegg, Tesla, or Netflix?
May 14, 2020
Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
April 14, 2020
People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our...
We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we...
- My$99Insulin: All patients can purchase up to three vials or two packs of FlexPen®/FlexTouch®/Penfill® pens of any combination of insulins from Novo Nordisk Inc. for $99
New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic
November 19, 2019
Emerging research begins to identify neighborhood characteristics that could impact the incidence of and vulnerability to chronic disease
Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral
August 14, 2019
Novo Nordisk to award promising start-ups free space at Boston's premier, biotech-capable shared lab facility
ESPEROCT® is now approved in Canada for the Treatment of Hemophilia A in both Children and Adults
July 12, 2019
New $70 million investment in 105-megawatt solar panel installation in North Carolina underscores 'Circular for Zero' commitment to environment
Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
February 28, 2019
Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100...
Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
February 10, 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GameStop Corp. (NYSE:GME),...
Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
January 23, 2019
Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
October 26, 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Paratek Pharmaceuticals,...
Google, Disney and LEGO Lead the World in Corporate Responsibility
October 11, 2018
2018 Global CR RepTrak® 100 Ranking Reveals New Era of Corporate Responsibility – Encompassing Good Will, Good Values and Good Business
Health Canada approves TRESIBA® for children with Type 1 diabetes
October 01, 2018
Research Report Identifies EnLink Midstream Partners, LP, Methanex, Novo Nordisk A/S, Magellan Midstream Partners, Arch Capital Group, and KT with Renewed Outlook — Fundamental Analysis, Calculating F
September 26, 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnLink Midstream Partners,...
Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus
September 21, 2018
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
September 11, 2018
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported operating and financial...
EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
September 10, 2018
EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of...
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products, today announced the appointment of Göran Ando, M.D.,...
Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo® in real-world evidence study
June 23, 2018
Sanofi, Genentech and Celgene Lead the Way in Reputation Institute’s 2018 US Pharma RepTrak®, The Largest Study on Reputation of Pharmaceutical Brands in the US
June 14, 2018
Findings reveal critical importance of ethical governance as prevailing disruption and erosion of trust cause major shake-up in pharma company reputations
New Research: Key Drivers of Growth for ObsEva SA, Gran Tierra Energy, Novo Nordisk A/S, HudBay Minerals, Tecnoglass, and Endeavour Silver — Factors of Influence, Major Initiatives and Sustained Produ
June 07, 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ObsEva SA (NASDAQ:OBSV),...
Emisphere Development Update
May 31, 2018
Novo Nordisk (NYSE:NVO) announced Tuesday the completion of the second phase 3a trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment...
Report: Developing Opportunities within El Pollo Loco, Chemed, Novo Nordisk A/S, FactSet Research, Fair Isaac, and HCP — Future Expectations, Projections Moving into 2018
May 22, 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of El Pollo Loco Holdings,...
3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2